Sophiris Bio (NASDAQ: SPHS) and Patheon (NYSE:PTHN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Insider & Institutional Ownership

5.5% of Sophiris Bio shares are held by institutional investors. Comparatively, 0.6% of Patheon shares are held by institutional investors. 3.9% of Sophiris Bio shares are held by insiders. Comparatively, 0.1% of Patheon shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Sophiris Bio has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500. Comparatively, Patheon has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Sophiris Bio and Patheon, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sophiris Bio 0 0 4 0 3.00
Patheon 0 6 1 0 2.14

Sophiris Bio presently has a consensus price target of $6.25, suggesting a potential upside of 204.88%. Patheon has a consensus price target of $33.60, suggesting a potential upside of Infinity. Given Patheon’s higher possible upside, analysts clearly believe Patheon is more favorable than Sophiris Bio.


This table compares Sophiris Bio and Patheon’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sophiris Bio N/A -85.20% -38.89%
Patheon N/A N/A N/A

Valuation and Earnings

This table compares Sophiris Bio and Patheon’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sophiris Bio N/A N/A -$11.16 million ($0.13) -15.77
Patheon $1.87 billion 0.00 $31.70 million $0.75 N/A

Patheon has higher revenue and earnings than Sophiris Bio. Sophiris Bio is trading at a lower price-to-earnings ratio than Patheon, indicating that it is currently the more affordable of the two stocks.


Patheon beats Sophiris Bio on 7 of the 12 factors compared between the two stocks.

Sophiris Bio Company Profile

Sophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio, Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin, INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate, PRX302, which has completed three clinical trials for the treatment of BPH, as well as two clinical trials for the treatment of localized recurrent prostate cancer.

Patheon Company Profile

Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product’s development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with's FREE daily email newsletter.